EGFR and neoplasm: The combination approach including JNJ- 61186372 could prevent or delay resistance to EGFR TKI, by acting on multiple clonal populations with varying EGFR mutations within the same tumor, more complete suppression of the EGFR pathway, and by parallel inhibition of c-Met.16